Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study.

Er F, Aslan O, Caglayan E, Gassanov N, Nia AM, Erdmann E, Rosenkranz S.

Clin Res Cardiol. 2010 Jun;99(6):369-73. doi: 10.1007/s00392-010-0129-7. Epub 2010 Feb 24.

PMID:
20180126
2.

Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation.

Climent VE, Marin F, Mainar L, Gomez-Aldaravi R, Martinez JG, Chorro FJ, Roman P, Sogorb F.

Pacing Clin Electrophysiol. 2004 Mar;27(3):368-72.

PMID:
15009866
3.

Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide.

Peters FP, Braat SH, Heymeriks J, Wellens HJ.

Neth J Med. 1998 Sep;53(3):93-6.

PMID:
9803139
4.

Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation.

Boriani G, Biffi M, Capucci A, Bronzetti G, Ayers GM, Zannoli R, Branzi A, Magnani B.

J Am Coll Cardiol. 1999 Feb;33(2):333-41.

5.
6.
7.

Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.

Kirchhof P, Fetsch T, Hanrath P, Meinertz T, Steinbeck G, Lehmacher W, Breithardt G.

Am Heart J. 2005 Nov;150(5):899.

PMID:
16290956
8.

Pharmacological cardioversion of atrial fibrillation: current management and treatment options.

Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A.

Drugs. 2004;64(24):2741-62. Review.

PMID:
15563247
9.

Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods.

Naegeli B, Straumann E, Bertel O.

Int J Cardiol. 2005 Mar 18;99(2):283-7.

PMID:
15749188
10.

Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study.

Okishige K, Nishizaki M, Azegami K, Igawa M, Yamawaki N, Aonuma K; Kanagawa Arrhythmia Task Force investigators..

Am Heart J. 2000 Sep;140(3):e13.

PMID:
10966544
11.

Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation.

Tuinenburg AE, Van Gelder IC, Van Den Berg MP, Brügemann J, De Kam PJ, Crijns HJ.

Heart. 1999 Oct;82(4):486-93.

12.
14.

Atrial fibrillation: rate control often better than rhythm control.

[No authors listed]

Prescrire Int. 2004 Apr;13(70):64-9.

PMID:
15148984
15.

Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation.

Khan IA, Mehta NJ, Gowda RM.

Int J Cardiol. 2003 Jun;89(2-3):239-48. Review.

PMID:
12767548
16.

Impact of serum flecainide level on control of atrial fibrillation in a case treated with cardiac resynchronization therapy.

Doki K, Homma M, Kuga K, Kawano S, Aonuma K, Yamaguchi I, Kohda Y.

J Clin Pharm Ther. 2007 Aug;32(4):409-11.

PMID:
17635343
17.
18.
19.

VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).

De Simone A, De Pasquale M, De Matteis C, Canciello M, Manzo M, Sabino L, Alfano F, Di Mauro M, Campana A, De Fabrizio G, Vitale DF, Turco P, Stabile G.

Eur Heart J. 2003 Aug;24(15):1425-9.

PMID:
12909071
20.

Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset.

Reisinger J, Gatterer E, Lang W, Vanicek T, Eisserer G, Bachleitner T, Niemeth C, Aicher F, Grander W, Heinze G, Kühn P, Siostrzonek P.

Eur Heart J. 2004 Aug;25(15):1318-24.

PMID:
15288159

Supplemental Content

Support Center